2023-04-27 16:05:38 ET
- PTC Therapeutics press release ( NASDAQ: PTCT ): Q1 GAAP EPS of -$1.88 misses by $0.47 .
- Revenue of $220.4M (+47.9% Y/Y) beats by $19.92M .
- Net loss was $139.0 million for the first quarter of 2023, compared to net loss of $126.7 million for the first quarter of 2022.
- Cash, cash equivalents, and marketable securities was $286.3 million at March 31, 2023, compared to $410.7 million at December 31, 2022.
-
PTC Reaffirms Full Year 2023 Revenue Guidance as Follows:
-
PTC anticipates total revenues for the full year 2023 to be between $940 million and $1.0 billion.
-
PTC anticipates net product revenues for the DMD franchise for the full year 2023 to be between $545 and $565 million.
For further details see:
PTC Therapeutics GAAP EPS of -$1.88 misses by $0.47, revenue of $220.4M beats by $19.92M